# Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy

> **NCT01187888** · PHASE3 · TERMINATED · sponsor: **Prof. Dr. Stefan Lorenzl** · enrollment: 44 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** Rasagiline
- **DRUG:** Sugar pill

## Key facts

- **NCT ID:** NCT01187888
- **Lead sponsor:** Prof. Dr. Stefan Lorenzl
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available for the study(pre-treatm.with Rasagiline=exclusion criterion
- **Last updated:** 2013-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01187888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01187888, "Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01187888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*